ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF

Title:

ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF

Document Type and Number:

WIPO Patent Application WO/2021/027850

Kind Code:

A1

Abstract:

Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.

More Like This:

WO/2023/156789	NOVEL METHODS OF THERAPY
JP2008189678	METHOD FOR EX VIVO IMMUNIZATION USING HETEROLOGOUS INTACT BISPECIFIC AND/OR TRISPECIFIC ANTIBODIES
JP2004531241	Nucleic acids of the human ABCC11 gene, vectors containing such nucleic acids, and their use

Inventors:

JIANG WENQING (CN)
FANG LEI (CN)
WANG ZHENGYI (CN)
GUO BINGSHI (CN)
PARK EUNYOUNG (KR)
SUNG EUNSIL (KR)
SUNG BYUNGJE (KR)

Application Number:

PCT/CN2020/108707

Publication Date:

February 18, 2021

Filing Date:

August 12, 2020

Export Citation:

Click for automatic bibliography generation Help

Assignee:

I MAB BIOPHARMA CO LTD (CN)
I MAB BIOPHARMA US LTD (US)
ABL BIO INC (KR)

International Classes:

C07K16/28; A61K39/395; A61P35/00; C12N15/13

Domestic Patent References:

WO2018140831A2	2018-08-02
WO2014075788A1	2014-05-22
WO2018119001A1	2018-06-28
WO2017143156A1	2017-08-24
WO2018114748A1	2018-06-28
WO2018114754A1	2018-06-28
WO2014075697A1	2014-05-22

Foreign References:

US5892019A	1999-04-06
US6150584A	2000-11-21
US6458592B1	2002-10-01
US6420140B1	2002-07-16

Other References:

JIANG，H. ET AL.: "Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 111, no. 4, 6 September 2018 (2018-09-06), pages 409 - 418, XP055642983, DOI: 20201029092055A
"Current Protocols in Molecular Biology", 2007
HAMERS-CASTERMAN ET AL., NATURE, vol. 363, 1993, pages 446 - 448
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1983, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
CHOTHIA ET AL., J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
ROUX ET AL., J. IMMUNOL, vol. 161, 1998, pages 4083
ARNON ET AL.: "Monoclonal Antibodies And Cancer Therapy", 1985, ALAN R. LISS, INC., article "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", pages: 243 - 56
HELLSTROM ET AL.: "Controlled Drug Delivery", 1987, MARCEL DEKKER, INC., article "Antibodies For Drug Delivery", pages: 623 - 53
THORPE ET AL.: "Monoclonal Antibodies '84: Biological And Clinical Applications", 1985, article "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", pages: 475 - 506
"Monoclonal Antibodies For Cancer Detection And Therapy", 1985, ACADEMIC PRESS, article "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", pages: 303 - 16
THORPE ET AL.: "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", IMMUNOL. REV., vol. 52, 1982, pages 119 - 58, XP001179872, DOI: 10.1111/j.1600-065X.1982.tb00392.x
See also references of EP 3853257A4

Attorney, Agent or Firm:

SHANGHAI BESHINING LAW OFFICE (CN)

Download PDF:

View/Download PDF PDF Help

Previous Patent: QUASI CO-LOCATION HYPOTHESIS DETERMINATION METHOD AND APPARATUS, STORAGE MEDIUM AND ELECTRONIC APPAR...

Next Patent: TROP2 ANTIBODY, PREPARATION METHOD THEREFOR, AND CONJUGATE AND USE THEREOF